A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • In the media
  • IP Watch covers WIPO Global Challenges semina...
Media - published on 17 Nov 2017

IP Watch covers WIPO Global Challenges seminar featuring Access to Vaccines Index

IP Watch features an article about the WIPO Global Challenges Seminar on access to vaccines that was organised in cooperation with the World Health Organization (WHO) and the Access to Medicine Foundation. 

The seminar took place on November 8, 2017, in Geneva, Switzerland. It explored how biopharmaceutical and vaccine manufacturers can play a role in improving access to current and future vaccines. During her presentation, Jayasree discussed how vaccine companies are responding to global calls to increase access to vaccines, drawing on findings from the Foundation’s Access to Vaccines Index, published in March 2017.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |